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ABSTRACT 
Background and Objectives: The prognosis and natural history of bradycardia related to drugs such as beta-
blockers and non-dihydropyridine calcium channel blockers are not well known. Subjects and Methods: We 
retrospectively analyzed 38 consecutive patients (age 69±11, 21 women) with drug-related bradycardia (DRB) 
between March 2005 and September 2007. A drug-associated etiology for the bradycardia was established based 
on the medical history and patient response to drug discontinuation. The mean follow-up duration was 18±8 
months. Results: The initial electrocardiogram (ECG) showed sinus bradycardia (heart rate ≤40/min) in 13 
patients, sinus bradycardia with junctional escape beats in 18 patients, and third-degree atrioventricular (AV) block 
in seven patients. Drug discontinuation was followed by resolution of bradycardia in 60% of patients (n=23). 
Among them, five (17.8%) patients resumed taking the culprit medication after discharge and none developed 
bradycardia again. Bradycardia persisted in 10 (26.3%) patients despite drug withdrawal, and a permanent pace-
maker was implanted in seven of them. Third-degree AV block, QRS width, and bradycardia requiring temporary 
transvenous pacing were significantly associated with the bradycardia caused by drugs. Conclusion: Beta-blockers 
were the most common drugs associated with DRB. However, in one quarter of the cases the DRB was not asso-
ciated with drugs; in these patients permanent pacemaker implantation should be considered. (Korean Circ J 2009; 
39:367-371) 
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Introduction 
 
According to the current guidelines of the Ameri-
can College of Cardiology/American Heart Association 
for pacemaker implantation, clinically significant symp-
tomatic bradycardia is one of the major indications for 
pacemaker implantation.
1) However, if symptomatic bra-
dycardia is drug-induced and the condition is expected 
to resolve after withdrawal of the culprit medication, pa-
cemaker implantation is generally considered unneces-
sary.
1) Clinically significant bradycardia can be induced 
by beta-blockers and non-dihydropyridine (DHP) cal-
cium-channel antagonists such as verapamil and diltia-
zem. Although drug-related bradycardia is frequently 
observed in clinical practice, it is a poorly defined cli-
nical problem. It is unclear whether drug-related bra-
dycardia (DRB) represents the presence of serious un-
derlying sinus and/or atrioventricular (AV) node dys-
function and conduction disturbance. Therefore, the aim 
of this study was to assess the prognosis and natural his-
tory of DRB. 
 
Subjects and Methods 
 
Study subjects 
In this retrospective study, we reviewed all cases that 
visited the emergency departments of three university 
hospitals (Kyungpook National University Hospital, Kei-
myung University Dongsan Medical Center, and Daegu 
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Catholic University Medical Center) in Daegu, Korea, 
between March 2005 and September 2007 with a dia-
gnosis of DRB. Thirty-eight consecutive patients that 
were regularly taking beta-blockers and/or non-DHP 
calcium channels antagonists were included.   
Patients were included in this study if they present-
ed with any of the following four electrocardiogram 
(ECG)-predefined cardiac rhythm abnormalities: 1) si-
nus bradycardia (≤40 beats/min), 2) sinus bradycar-
dia with junctional escape beats, 3) second-degree AV 
block, and 4) third-degree AV block. Patients were ex-
cluded if their bradycardia was attributed to an acute 
myocardial infarction, other anti-arrhythmic drugs, di-
gitalis toxicity, electrolyte imbalances, or failure of a pre-
viously implanted pacemaker device.   
 
Cause-and-effect relationship between drugs and 
bradycardia 
The cause-and-effect relationship between medica-
tion use and bradycardia was defined according to the 
response to drug discontinuation. Patients were clas-
sified into one of the three following groups: 1) DRB 
caused by drugs: DRB that resolved within 48 hours 
after drug withdrawal and never recurred during the 
follow-up period; 2) DRB not caused by drugs: DRB 
that persisted after drug withdrawal or recurred in the 
absence of drug therapy during the follow-up period; 
3) DRB undetermined correlation: bradycardia that re-
solved within 48 hours after drug withdrawal, but the 
cause-and-effect relationship could not be determined 
because the bradycardia did not recur despite restart-
ing drug therapy during the follow-up period. 
 
Follow-up and outcome 
The mean follow-up duration was 18±8 months. Th-
erapies with beta-blockers and/or non-DHP calcium 
channel blockers were discontinued soon after admis-
sion. The recurrence of clinically significant and symp-
tomatic bradycardia during the follow-up period was 
assessed. All patients were asked to report their symp-
toms at their out-patient clinic visits or during phone 
interviews. 
 
Statistical analysis 
The data are expressed as the mean±SD or percen-
tages. Patients were categorized into the three previously 
mentioned groups. All comparisons between the base-
line variables were assessed with the Chi-square test or 
the analysis of variance (ANOVA) test for categorical 
or continuous variables, respectively. The Least Signi-
ficant Difference (LSD) post hoc test was performed to 
investigate significant differences among the three groups. 
For all analyses, a two-sided p<0.05 was considered sta-
tistically significant. Statistical analysis was performed 
using Statistical Package for Social Science (SPSS) ver-
sion 15.0 for Windows (SPSS Inc., Chicago, IL, USA). 
 
Results 
 
Patients, their symptoms, and presenting rhythms 
Baseline characteristics of the study population are 
shown in Table 1. The mean age was 68±11 years, and 
21  (55.3%) patients were women. Sinus bradycardia 
with junctional escape beats was the most common ECG 
finding and was identified in 18 (47.4%) patients. Si-
nus bradycardia was noted in 13 (34.2%) patients, and 
third-degree AV block in seven (18.4%) patients. There 
was no patient with a second-degree AV block. Thirty-
four (89.5%) patients were on beta-blockers and nine 
(23.7%) were on non-DHP calcium channel blockers. 
Five (13.2%) patients were on both beta-blockers and 
non-DHP calcium channel blockers. 
The indications for treatment with these drugs were 
hypertension (n=29) and ischemic heart disease (n= 
21). The most common symptom was presyncope (n= 
17), followed by syncope (n=8), chest discomfort (n= 
8), and dyspnea (n=5). There were no significant dif-
ferences in symptoms according to the type of ECGs 
(p=0.09). The mean time from initiation of the first 
symptom suggestive of bradycardia to admission was 3.9 
days. Two-dimensional echocardiography was perform-
ed in all patients and it showed a mean left ventricular 
ejection fraction (LVEF) of 61.7±11.3%. The mean QRS 
duration was 97.9±17.3 msec. Temporary pacing was 
provided in 11 (28.9%) patients. 
Patients with “DRB caused by drugs” were similar to 
those with “DRB not caused by drugs” or “undetermin-
ed correlation” with regard to the demographic features, 
underlying diseases, presenting symptoms, symptom 
duration, laboratory findings, LVEF, and medication 
history (Table 1). There were no significant differences 
in the mean duration of medication among the three 
groups (p=0.073). The mean duration of medication 
tended to be longer among the patients with “DRB not 
caused by drugs” compared to the patients with “DRB 
caused by drugs” (p=0.140). The median duration of 
medication was three and 21 months in the “DRB caus-
ed by drugs” and in the “DRB not caused by drugs”, 
respectively. There were significant differences among 
the three groups in the ECG characteristics: patients 
with “DRB caused by drugs” more commonly had si-
nus bradycardia with junctional escape beats and less 
commonly third-degree AV block; patients with “DRB 
not caused by drugs” more commonly had third-de-
gree AV block, whereas patients with “bradycardia of 
undetermined correlation” more commonly had sinus 
bradycardia (p=0.002). The QRS width in the patients 
with “DRB not caused by drugs” was significantly long-
er than in the patients with “DRB caused by drugs” or 
“bradycardia of undetermined correlation” (p=0.031).  
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Compromising bradycardia requiring temporary trans-
venous pacing was more common in the patients with 
“DRB not caused by drugs” (p=0.038).  
 
Clinical course after medication withdrawal 
The culprit medications were discontinued in all pa-
tients soon after hospitalization (Fig. 1). Drug discon-
tinuation was followed by spontaneous resolution of 
bradycardia within 48 hours in 28 (73.7%) out of 38 
patients. Five among them resumed taking the culprit 
medication after discharge, and none of these patients 
developed bradycardia again during the follow-up pe-
riod; their bradycardia was classified as “undetermined 
correlation”. The bradycardia in the remaining 23 (60.5% 
out of 38 patients was considered “DRB caused by drugs”. 
The bradycardia persisted in 10 (26.3%) patients des-
Table 1. Baseline characteristics of 38 patients with drug-related bradycardia
  Entire population 
(n=38) 
DRB caused by 
drugs (n=23) 
DRB not caused 
by drugs (n=10) 
Undetermined 
correlation (n=5) 
p 
Demographics 
Age (years) 
Female (%) 
Height (cm) 
Weight (kg) 
Body mass index (kg/m
2) 
 
68.8±11.4 
21 (55.3) 
160.9±7.3 
61.6±9.8 
24.3±3.7 
 
70.0±8.5 
14 (60.9) 
159.9±7.2 
63.8±11.0 
25.4±4.0 
 
70.6±7.2 
06 (60.0) 
160.9±6.9 
57.0±6.7 
22.4±2.5 
 
59.8±23.6 
01 (20.0) 
165.7±9.8 
62.7±8.7 
22.8±2.4 
 
0.161 
0.170 
0.479 
0.251 
0.129 
Underlying disease (%) 
Hypertension  
Diabetes  
Ischemic heart disease   
 
29 (76.3) 
12 (31.6) 
21 (55.3) 
 
19 (82.6) 
08 (34.8) 
12 (52.2) 
 
08 (80.0) 
03 (30.0) 
06 (60.0) 
 
02 (40.0) 
01 (20.0) 
03 (60.0) 
 
0.086 
0.527 
0.670 
Presentation (%) 
Syncope  
Presyncope 
Dyspnea 
Chest discomfort   
 
08 (21.1) 
17 (44.7) 
05 (13.2) 
08 (21.1) 
 
04 (17.4) 
09 (39.1) 
04 (17.4) 
06 (26.1) 
 
02 (20.0) 
05 (50.0) 
01 (10.0) 
02 (20.0) 
 
02 (40.0) 
03 (60.0) 
0 (0.0) 
0 (0.0) 
0.090 
 
 
 
 
Symptom duration (days)  3.9±5.6 2.6±2.9 6.2±8.8 5.8±6.2 0.184 
Mean duration of medication use 
 (months)  (median,  range) 
24 (6, 0.07-180)  13 (3, 0.07-84)  50 (21, 1-180)  12 (12, 0.7-22) 0.073 
Electrolytes 
Na (mmol/L) 
K (mmol/L) 
Ca (mg/dL) 
 
138.7±5.3 
4.7±0.9 
8.7±0.6 
 
139.1±4.7 
4.9±0.9 
8.7±0.7 
 
139.8±6.7 
4.4±0.8 
8.7±0.5 
 
139.4±4.5 
4.1±0.8 
8.5±0.6 
 
0.945 
0.140 
0.779 
Renal function (mg/dL) 
BUN 
Creatinine 
 
24.5±10.9 
1.4±0.8 
 
25.4±10.0 
1.3±0.4 
 
22.7±9.7 
1.5±1.2 
 
24.0±17.7 
1.5±1.1 
 
0.811 
0.829 
Cardiac rhythm at presentation (%)          0.002 
Sinus bradycardia (≤40/min)   13  (34.2)  08 (34.8)  02 (20.0)  03 (60.0)   
Sinus bradycardia with junctional 
 escape  beats 
18 (47.4)  14 (60.9)  02 (20.0)  02 (40.0)   
Second-degree AV block  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)   
Third-degree AV block  07 (18.4)  1 (4.3)  06 (60.0)  0 (0.0)   
QRS width (ms)  97.9±17.3 94.1±9.9 109.3±24.9 87.8±9.1 0.031 
Left ventricular ejection fraction (%)  61.7±11.3 61.5±11.8 60.1±12.7 65.4±6.4 0.716 
Temporary transvenous pacing (%)  11 (28.9)  03 (13.0)  06 (60.0)  02 (40.0)  0.038 
Medications (%) 
Beta-blocker  
Atenolol 
Propranolol 
Carvedilol 
Bisoprolol 
Betaxolol 
Non-DHP CCB 
Diltiazem 
Verapamil 
 
34 (89.5) 
13 (34.2) 
05 (13.2) 
12 (31.6) 
3 (7.9) 
1 (2.6) 
09 (23.7) 
08 (24.3) 
1 (2.7) 
 
19 (82.6) 
09 (39.1) 
1 (4.3) 
06 (26.1) 
2 (8.7) 
1 (4.3) 
08 (34.8) 
07 (30.4) 
1 (4.3) 
 
10 (100.0) 
03 (30.0) 
01 (10.0) 
05 (50.0) 
01 (10.0) 
0 (0.0) 
01 (10.0) 
01 (10.0) 
0 (0.0) 
 
5 (100.0) 
01 (20.0) 
03 (60.0) 
01 (20.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
0.125 
0.351 
 
 
 
 
0.125 
0.147 
 
DRB: drug-related bradycardia, BUN: blood urea nitrogen, AV: atrioventricular, Non-DHP CCB: Non-dihydropyridine calcium channel blocker 
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pite drug withdrawal. Therefore, they were considered 
“DRB not caused by drugs”. Permanent pacemaker im-
plantation was performed in seven of the 10 patients 
with “DRB not caused by drugs”. The cardiac rhythms 
in the seven patients requiring permanent pacing were 
sinus bradycardia in one; sinus bradycardia with junc-
tional escape beats in one; and third-degree AV block 
in five. 
 
Discussion 
 
We present data on 38 patients with clinically signi-
ficant and symptomatic DRB responsible for the deve-
lopment of syncope, presyncope, dyspnea, and chest 
discomfort. All patients were on beta-blockers and/or 
non-DHP calcium channels antagonists at the time of 
presentation. The main findings of this retrospective 
analysis were that about one quarter of the DRB was 
not caused by, but revealed by drugs, and that beta-
blockers were the most common ‘offending’ drug in-
volved in the development of bradycardia. 
 
Does drug-related bradycardia suggest a benign 
prognosis? 
When symptomatic bradycardia is related to extrin-
sic causes, removal of potentially reversible causes of the 
bradycardia is always the first approach to management.
2-4) 
Severe symptomatic bradycardia has been observed dur-
ing therapy with beta-blockers and non-DHP calcium 
channels antagonists.
3-5) In patients with clinically sig-
nificant bradycardia secondary to drug treatment, one 
must decide whether to discontinue, reduce the dosage, 
or continue medication use if there is no acceptable 
alternative; in the latter case pacing therapy should be 
considered.
1) Such decisions are presently being made 
on the basis of clinical judgment rather than publi-
shed guidelines because little is known about the prog-
nosis and natural history of patients with drug-related 
bradycardia.
6) A recent study reported that druginduc-
ed AV block, in patients treated with beta-blockers and 
non-DHP calcium channels antagonists, the AV block 
‘truly caused by drugs’ was found in only 15% of the pa-
tients, and in the majority of cases, the ‘culprit’ drugs 
were found to be ‘innocent bystanders’.
7) 
It is possible that clinically significant and sympto-
matic ‘drug-induced’ bradycardia in other patients might 
also be primarily due to underlying sinus and/or AV 
node disease.
6)8-10) It is often reported in the literature 
that therapeutic doses of drugs, generally, do not cause 
clinically significant bradycardia in patients with struc-
turally normal hearts
9-12); however, in the heart with 
underlying latent disease of the sinus and/or AV node, 
bradycardia may occur due to a triggering effect caused 
by drug-related bradycardia. Bradycardia usually develops 
after prolonged medication use in these cases,
10-12) and 
may have different underlying mechanisms than in cases 
associated with true pro-arrhythmic events. The true pro-
arrhythmic events commonly occur within several days 
from the start of anti-arrhythmic drug therapy at initial 
relatively low doses. When significant bradycardia is 
observed in patients taking drugs such as beta-blockers 
and/or non-DHP calcium channel antagonists, the pos-
sibility of significant underlying sinus or conduction sys-
tem disease or both must be considered. 
 
Prediction of drug-related bradycardia from the me-
dication history and electrocardiogram findings 
Combined drug therapy, advanced age, a history of 
prior myocardial infarction, decreased systolic perform-
ance, and ventricular arrhythmia increase the risk of 
bradyarrhythmic complications associated with drug 
therapy.
2)8)12) In a study of patients with high-degree AV 
block, a QRS width  ≥120 ms was an independent pre-
dictor for the progression of a high-degree AV block 
after drug withdrawal.
13) In this study, third-degree AV 
block, QRS width, and bradycardia requiring tempo-
Bradycardia not recurred 
(undetermined)(n=5) 
Bradycardia caused   
by drugs (n=23) 
Bradycardia not caused 
by drugs (n=10) 
Drug restarted 
(n=5) 
PM implanted 
(n=7) 
PM not implanted 
(n=3) 
Bradycardia persisted 
(n=10) 
Bradycardia resolved 
(n=28) 
Drugs stopped 
(n=38) 
Drug-related bradycardia 
(n=38) 
Fig. 1. Flow chart describing the clinical course of 38 patients with drug-related bradycardia. PM: pacemaker.  
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rary transvenous pacing were significantly associated with 
bradycardia in cases truly associated with drugs.   
 
Permanent pacing in drug-related bradycardia 
There is a paucity of data regarding the incidence of 
drug-related bradycardia in specific cardiac condi-
tions.
9)14)15-17) In a recent report, the incidence of drug-
related bradycardia requiring permanent pacing was 
estimated to be 1-15% among patients on a variety of 
anti-arrhythmic agents used for different indications. 
6) 
In another report, resolution of an AV block with drug 
discontinuation was more likely to be transient, and 
the reported 56% rate of “AV block relapse” was likely 
an underestimation; additional cases might have been 
detected with a longer follow-up.
7) Although these pa-
tients could be discharged without permanent pacing, 
according to current guidelines,
1) it was suggested that 
pacemaker implantation should be considered in such 
patients.
7) 
The limitations of this study included the following. 
First, the retrospective nature of the analysis and the 
small sample size are major limitations and increase 
the likelihood of a selection bias. Second, the relative 
short follow-up period in some patients might have 
underestimated the frequency of bradycardia truly caus-
ed by drugs. Third, we did not perform a sinus node 
function test. Sinus node function testing is not indi-
cated in patients with DRB according to the Korean 
National Health Insurance System guidelines. Fourth, 
we did not perform routine 24 hour ECG monitoring. 
Patients might have asymptomatic sinus bradycardia or 
AV block that would be identified during 24 hour ECG 
monitoring. We only evaluated symptomatic bradycar-
dia as a possible indication for pacemaker implanta-
tion in this study. Fifth, we could not perform a multi-
variate analysis because of the small sample size, and 
independent predictors of bradycardia truly associated 
with drugs could not be established in this study. 
In conclusion, beta-blockers were the most common 
drugs associated with the development of bradycardia. 
About one quarter of the cases with DRB were not 
caused by drugs, but were revealed by drugs. Close fol-
low-up of these patients is needed because implanta-
tion of a permanent pacemaker may be required in some 
of them. 
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